NPI 1528037082: Open Payments
NPI 1528037082. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,150 in 113 payments from 14 companies in 2025. Trend: 2023 $1,714 · 2024 $2,238 · 2025 $2,150
Food & beverage: $2,150
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $296 |
| ABBVIE INC. | 23 | $280 |
| Alkermes, Inc. | 11 | $264 |
| Lundbeck LLC | 12 | $218 |
| E.R. Squibb & Sons, L.L.C. | 10 | $190 |
| Teva Pharmaceuticals USA, Inc. | 10 | $184 |
| Janssen Pharmaceuticals, Inc | 6 | $180 |
| Corium, LLC | 11 | $172 |
| Axsome Therapeutics, Inc. | 4 | $114 |
| Vanda Pharmaceuticals Inc. | 4 | $82 |
Products named: REXULTI, VRAYLAR, COBENFY, Azstarys, SPRAVATO, AUSTEDO XR, LYBALVI, ARISTADA.
